| OS at 36 months | P-value | EFS at 36 months | P-value |
Study patients (n = 73) | 63.3% |
| 51.3% |
|
Age (years) < 1.5 ≥ 1.5 < 5 ≥ 5 |
66.7% 58.7% 73.8% | 0.31 |
66.6% 46.7% 66.2% | 0.49 |
Stage III IV |
68.1% 62.7% | 0.54 |
52.6% 51.0% | 0.626 |
MYCN status Amplified Not amplified Unknown |
51.1% 63.1% 100% | 0.428 |
49.0% 52.6% 50.0% | 0.96 |
Bone marrow infiltration No Yes Unknown |
70.7% 59.3% 100% | 0.15 |
58.9% 46.8% 0% | 0.15 |
Bone metastasis No Yes Unknown |
62.2% 63.5% 100% | 0.402 |
56.1% 44.4% 100% | 0.09% |
Brain metastasis No Yes |
69.4% 83.3% | 0.425 |
48.7% 83.3% | 0.211 |
Liver metastasis No Yes |
64.5% 33.3% | 0.236 |
51.9% 33.3% | 0.499 |
Distant lymph node involvement No Yes |
68.1% 61.6% | 0.08 |
55.1% 50.1% | 0.44 |
Post-induction CTh response CR/VGPR/PR Less than PR |
64.2% 63.5% | 0.75 |
53.3% 49.3 | 0.45 |
Extent of surgical resection Complete resection Less than complete resection No surgical intervention |
50.5% 56.3% 75.1% | 0.4 |
42.7% 41.7 63.7% | 0.44 |
Disease status at time of transplant CR/VGPR/PR |
60.7% 81.8% | 0.34 |
50.1% 60.6% | 0.54 |